FDA announces safety labeling changes and postmarket study requirements for extended-release and long-acting opioid analgesics
The U.S. Food and Drug Administration today announced class-wide safety labeling changes and new postmarket study requirements for all extended-release and long-acting (ER/LA) opioid analgesics intended to treat pain.
